Ethris GmbH. (8/21/17). "Press Release: Ethris Enters Strategic Collaboration with AstraZeneca and MedImmune to Develop mRNA Therapies for Respiratory Diseases". Munich & Gaithersburg, MD.

	Organisation	Ethris GmbH
	Organisation 2	MedImmune (biologics division of AstraZeneca)
	Group	AstraZeneca (Group)
	Product	SNIM®RNA technology
	Product 2	mRNA-based drug
	Index term	AstraZeneca–Ethris: mRNA-based therapeutics, 201708– collab research 5y w €25m upfront + funding + milestones using SNIM®RNA technology
	Person	Rudolph, Carsten (Ethris 201301 Managing Director + Co-Founder)
	Person 2	Jallal, Bahija (Immunocore 201901– CEO before AstraZeneca President MedImmune joined MedImmune 2006)

Ethris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, today announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on developing new stabilised non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM®RNA technology.

Ethris will receive €25 million upfront plus research funding and is eligible for future research and development milestones, including sales related royalties upon commercialisation. AstraZeneca and MedImmune will have the option to take exclusive worldwide licenses upon completion of the research plan for each target within the collaboration.

mRNA therapies deliver genetic instructions to cells which drive the target cells to produce selected proteins to help prevent or fight diseases. Ethris’ proprietary mRNA technology can be targeted to the lungs where it helps to replace, inhibit or augment proteins that are involved in causing or exacerbating respiratory disease. mRNA-based therapeutics may also provide new opportunities to modify the course of the disease or its symptoms.

Ethris will utilize its proprietary SNIM®RNA technology exclusively with AstraZeneca through the company’s MedImmune and Innovative Medicines (IMED) biotech units to develop multiple new targets for investigation in the diseases of asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Dr. Carsten Rudolph, President and CEO of Ethris, said: “This collaboration validates Ethris’ leading position in development and delivery of mRNA therapies for the treatment of pulmonary diseases. This collaboration pairs our proprietary technology with the world-class expertise of AstraZeneca and MedImmune in respiratory diseases, biologics development and commercialisation, and positions us to bring forward new options for patients.”

Bahija Jallal, Executive Vice President, MedImmune, added: “Rapid advances over the last decade have made mRNA a very promising tool for clinical application, and we are excited to collaborate with Ethris, whose advanced platform is leading in RNA delivery to the lung. This collaboration complements our respiratory science focused on early intervention and disease modification by adding novel ways to target disease mechanisms that cannot be addressed by other approaches currently in our pipeline.”

About Ethris:

Ethris is paving a new path from genes to therapeutic proteins using its proprietary messenger RNA technology platform, which enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. Ethris is advancing transcript therapies to transform the treatment of disease. For more information, visit www.ethris.com.

About MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit
www.astrazeneca.com and follow us on Twitter @AstraZeneca.

For more information please contact:

Ethris GmbH
Ilse Huebner-Seibl
+49-(0)89-8955-788 10 info@ethris.com

Media requests:
MacDougall Biomedical Communications
Mario Brkulj or Joanne Tudorica
Phone: +49 175 501 05 75 or +49 (0) 89 2424 3494
mbrkulj@macbiocom.com

Record changed: 2023-06-05